NCT04696718

Brief Summary

The main objective of the study is to determine the influence of patient sera before and after probiotic intervention on the behavior of bone cells (osteoblasts and osteoclasts). The secondary objectives are to assess the activity of bone cells and the course of rheumatoid arthritis before and after the consomption of probiotics.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 20, 2018

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

December 7, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 6, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2023

Completed
Last Updated

August 11, 2022

Status Verified

August 1, 2022

Enrollment Period

4 years

First QC Date

December 7, 2020

Last Update Submit

August 10, 2022

Conditions

Keywords

rheumatoid arthritisprobiotics

Outcome Measures

Primary Outcomes (1)

  • Change of biological activity of serum between day 0 to day 28

    Ex vivo quantification of the formation of osteoclast multi-nucleated cells following culture in the presence of metabolites from the serum of patients between day 0 and day 28

    Day 0 and Day 28

Secondary Outcomes (1)

  • Change of Disease Activity Score (DAS28) day 0 to day 28

    Day 0 and Day 28

Study Arms (3)

Traitement 1

EXPERIMENTAL

Lactobacillus salivarius

Dietary Supplement: daily supplementation

Traitement 2

EXPERIMENTAL

Lactobacillus Rhamnosus GG

Dietary Supplement: daily supplementation

Traitement 3

EXPERIMENTAL

Bifidobacterium lactis

Dietary Supplement: daily supplementation

Interventions

daily supplementationDIETARY_SUPPLEMENT

the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days

Traitement 1Traitement 2Traitement 3

Eligibility Criteria

Age30 Years - 75 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailshigher prevalency of RA in women
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women
  • years
  • Non-menopausal or menopausal for more than 2 years because the tissue osteoarticular is under the influence of steroid hormones. Peri-menopause is accompanied by strong hormonal variations.
  • With rheumatoid arthritis (DAS28 threshold specified below)
  • Clinical arthritis score ≥ 2.6 (DAS28). Pathology needs to be characterized even if the score remains low
  • Person with good venous condition

You may not qualify if:

  • Vaccination in the last two months
  • Alcohol abuse with regard to WHO standards
  • Smoking (\>5 cigarettes/day)
  • \> 5 hours of intense sport per week
  • Food allergy and others
  • Persons under guardianship, curators, deprived of liberties, safeguard of justice
  • Refusal to sign the information and consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Emile Roux

Le Puy-en-Velay, 43000, France

RECRUITING

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • benjamin castagne, MD

    Centre Hospitalier Emile Roux

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
single blind
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Crossover Assignment patient may receive 3 products in 3 interventions sequentially during the protocol
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical Research Associate

Study Record Dates

First Submitted

December 7, 2020

First Posted

January 6, 2021

Study Start

December 20, 2018

Primary Completion

December 22, 2022

Study Completion

December 28, 2023

Last Updated

August 11, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations